Expert Answers to HCP Questions on CAR T-Cell Therapy

In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including:At what time in the treatment journey should CAR T-cell therapy be considered?How to select among 3 approved products for relapsed/refractory large B-cell lymphoma?How is CAR T-cell therapy best used for multiple myeloma?What qualities of bridging therapy are most preferred?When do patients receiving CAR T-cell therapy need COVID-19 or other vaccinations?  How are steroids optimally used in managing CAR T-cell therapy–related toxicities?Presenters:Caron A. Jacobson, MDAssistant ProfessorDivision of Medical OncologyDepartment of MedicineHarvard Medical SchoolDana-Farber Cancer InstituteBoston, MassachusettsJae H. Park, MDAssociate Member  Leukemia Service and Cellular Therapeutics Center  Memorial Sloan Kettering Cancer CenterNew York, New YorkNoopur Raje, MDDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer Center  Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by an educational grant from Bristol-Myers Squibb.Link to full program:https://bit.ly/3BfbEOf